{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:15:16Z","timestamp":1793142916187,"version":"4.5.0"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurosci. Bull."],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s12264-025-01525-x","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T12:32:14Z","timestamp":1761395534000},"page":"1706-1724","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Preventive Memantine Treatment at the Preclinical Stage in the Alzheimer\u2019s Disease Model of the 5xFAD Mouse"],"prefix":"10.1007","volume":"42","author":[{"given":"Xiaohuan","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1335-1398","authenticated-orcid":false,"given":"Shan Ping","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Q.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananth","family":"Sastry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,25]]},"reference":[{"key":"1525_CR1","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JA Hardy","year":"1992","unstructured":"Hardy JA, Higgins GA. Alzheimer\u2019s disease: The amyloid cascade hypothesis. Science 1992, 256: 184\u2013185.","journal-title":"Science"},{"key":"1525_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.neuron.2014.05.041","volume":"83","author":"CM Karch","year":"2014","unstructured":"Karch CM, Cruchaga C, Goate AM. Alzheimer\u2019s disease genetics: From the bench to the clinic. Neuron 2014, 83: 11\u201326.","journal-title":"Neuron"},{"key":"1525_CR3","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1002\/alz.12124","volume":"16","author":"RJ Caselli","year":"2020","unstructured":"Caselli RJ, Knopman DS, Bu G. An agnostic reevaluation of the amyloid cascade hypothesis of Alzheimer\u2019s disease pathogenesis: The role of APP homeostasis. Alzheimers Dement 2020, 16: 1582\u20131590.","journal-title":"Alzheimers Dement"},{"key":"1525_CR4","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s12264-023-01025-w","volume":"39","author":"J Xiong","year":"2023","unstructured":"Xiong J, Zhang Z, Ye K. C\/EBP\u03b2\/AEP signaling drives Alzheimer\u2019s disease pathogenesis. Neurosci Bull 2023, 39: 1173\u20131185.","journal-title":"Neurosci Bull"},{"key":"1525_CR5","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/nn.4017","volume":"18","author":"K Herrup","year":"2015","unstructured":"Herrup K. The case for rejecting the amyloid cascade hypothesis. Nat Neurosci 2015, 18: 794\u2013799.","journal-title":"Nat Neurosci"},{"key":"1525_CR6","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1080\/13543784.2021.2017881","volume":"30","author":"BP Imbimbo","year":"2021","unstructured":"Imbimbo BP, Watling M. What have we learned from past failures of investigational drugs for Alzheimer\u2019s disease? Expert Opin Investig Drugs 2021, 30: 1175\u20131182.","journal-title":"Expert Opin Investig Drugs"},{"key":"1525_CR7","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s12264-024-01339-3","volume":"41","author":"YJ Jia","year":"2025","unstructured":"Jia YJ, Wang XY, Liu J, Wang YJ, Masters CL, Guo JH. Halting the progression of Alzheimer\u2019s disease: Is the goal in sight? Neurosci Bull 2025, 41: 723\u2013727.","journal-title":"Neurosci Bull"},{"key":"1525_CR8","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.neuron.2014.10.038","volume":"84","author":"R Sperling","year":"2014","unstructured":"Sperling R, Mormino E, Johnson K. The evolution of preclinical Alzheimer\u2019s disease: Implications for prevention trials. Neuron 2014, 84: 608\u2013622.","journal-title":"Neuron"},{"key":"1525_CR9","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jalz.2019.04.001","volume":"15","author":"L Vermunt","year":"2019","unstructured":"Vermunt L, Sikkes SAM, van den Hout A, Handels R, Bos I, van der Flier WM. Duration of preclinical, prodromal, and dementia stages of Alzheimer\u2019s disease in relation to age, sex, and APOE genotype. Alzheimers Dement 2019, 15: 888\u2013898.","journal-title":"Alzheimers Dement"},{"key":"1525_CR10","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jalz.2019.09.085","volume":"16","author":"RJ Caselli","year":"2020","unstructured":"Caselli RJ, Langlais BT, Dueck AC, Chen Y, Su Y, Locke DEC, et al. Neuropsychological decline up to 20 years before incident mild cognitive impairment. Alzheimers Dement 2020, 16: 512\u2013523.","journal-title":"Alzheimers Dement"},{"key":"1525_CR11","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/archneurol.2011.69","volume":"68","author":"LS Schneider","year":"2011","unstructured":"Schneider LS, Dagerman KS, Higgins JP, McShane R. Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol 2011, 68: 991\u2013998.","journal-title":"Arch Neurol"},{"key":"1525_CR12","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3233\/JAD-170424","volume":"60","author":"T Kishi","year":"2017","unstructured":"Kishi T, Matsunaga S, Oya K, Nomura I, Ikuta T, Iwata N. Memantine for Alzheimer\u2019s disease: An updated systematic review and meta-analysis. J Alzheimers Dis 2017, 60: 401\u2013425.","journal-title":"J Alzheimers Dis"},{"key":"1525_CR13","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1001\/jamainternmed.2023.8522","volume":"184","author":"DB Reuben","year":"2024","unstructured":"Reuben DB, Kremen S, Maust DT. Dementia prevention and treatment: A narrative review. JAMA Intern Med 2024, 184: 563\u2013572.","journal-title":"JAMA Intern Med"},{"key":"1525_CR14","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1468-1331.2009.02816.x","volume":"17","author":"PJ Modrego","year":"2010","unstructured":"Modrego PJ, Fayed N, Errea JM, Rios C, Pina MA, Sarasa M. Memantine versus donepezil in mild to moderate Alzheimer\u2019s disease: A randomized trial with magnetic resonance spectroscopy. Eur J Neurol 2010, 17: 405\u2013412.","journal-title":"Eur J Neurol"},{"key":"1525_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1159\/000430808","volume":"40","author":"N Zhang","year":"2015","unstructured":"Zhang N, Wei C, Du H, Shi FD, Cheng Y. The effect of memantine on cognitive function and behavioral and psychological symptoms in mild-to-moderate Alzheimer\u2019s disease patients. Dement Geriatr Cogn Disord 2015, 40: 85\u201393.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1525_CR16","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1097\/01.JGP.0000224350.82719.83","volume":"14","author":"ER Peskind","year":"2006","unstructured":"Peskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT, et al. Memantine treatment in mild to moderate Alzheimer disease: A 24-week randomized, controlled trial. Am J Geriatr Psychiatry 2006, 14: 704\u2013715.","journal-title":"Am J Geriatr Psychiatry"},{"key":"1525_CR17","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/WAD.0b013e318032cf29","volume":"21","author":"N Pomara","year":"2007","unstructured":"Pomara N, Ott BR, Peskind E, Resnick EM. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: Secondary analyses from a placebo-controlled randomized trial. Alzheimer Dis Assoc Disord 2007, 21: 60\u201364.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"1525_CR18","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1161\/01.STR.0000020094.08790.49","volume":"33","author":"JM Orgogozo","year":"2002","unstructured":"Orgogozo JM, Rigaud AS, St\u00f6ffler A, M\u00f6bius HJ, Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: A randomized, placebo-controlled trial (MMM 300). Stroke 2002, 33: 1834\u20131839.","journal-title":"Stroke"},{"key":"1525_CR19","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1177\/0300060517715166","volume":"45","author":"D Ilhan Algin","year":"2017","unstructured":"Ilhan Algin D, Dagli Atalay S, Ozkan S, Ozbabalik Adapinar D, Ak Sivrioz I. Memantine improves semantic memory in patients with amnestic mild cognitive impairment: A single-photon emission computed tomography study. J Int Med Res 2017, 45: 2053\u20132064.","journal-title":"J Int Med Res"},{"key":"1525_CR20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3233\/JAD-2008-13110","volume":"13","author":"S Bakchine","year":"2008","unstructured":"Bakchine S, Loft H. Memantine treatment in patients with mild to moderate Alzheimer\u2019s disease: Results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis 2008, 13: 97\u2013107.","journal-title":"J Alzheimers Dis"},{"key":"1525_CR21","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jalz.2013.03.007","volume":"9","author":"B Vellas","year":"2013","unstructured":"Vellas B, Carrillo MC, Sampaio C, Brashear HR, Siemers E, Hampel H, et al. Designing drug trials for Alzheimer\u2019s disease: What we have learned from the release of the phase III antibody trials: A report from the EU\/US\/CTAD task force. Alzheimers Dement 2013, 9: 438\u2013444.","journal-title":"Alzheimers Dement"},{"key":"1525_CR22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13024-023-00636-1","volume":"18","author":"SP Yu","year":"2023","unstructured":"Yu SP, Jiang MQ, Shim SS, Pourkhodadad S, Wei L. Extrasynaptic NMDA receptors in acute and chronic excitotoxicity: Implications for preventive treatments of ischemic stroke and late-onset Alzheimer\u2019s disease. Mol Neurodegener 2023, 18: 43.","journal-title":"Mol Neurodegener"},{"key":"1525_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1749-6632.1994.tb44398.x","volume":"747","author":"ZS Khachaturian","year":"1994","unstructured":"Khachaturian ZS. Calcium hypothesis of Alzheimer\u2019s disease and brain aginga. Ann N Y Acad Sci 1994, 747: 1\u201311.","journal-title":"Ann N Y Acad Sci"},{"key":"1525_CR24","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/nrn960","volume":"3","author":"FM LaFerla","year":"2002","unstructured":"LaFerla FM. Calcium dyshomeostasis and intracellular signalling in Alzheimer\u2019s disease. Nat Rev Neurosci 2002, 3: 862\u2013872.","journal-title":"Nat Rev Neurosci"},{"key":"1525_CR25","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1126\/science.318.5849.384","volume":"318","author":"M Jean","year":"2007","unstructured":"Jean M. Fresh evidence points to an old suspect: Calcium. Science 2007, 318: 384\u2013385.","journal-title":"Science"},{"key":"1525_CR26","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jalz.2016.12.006","volume":"13","author":"ZS Khachaturian","year":"2017","unstructured":"Khachaturian ZS. Calcium Hypothesis of Alzheimer\u2019s disease and brain aging: A framework for integrating new evidence into a comprehensive theory of pathogenesis. Alzheimers Dement 2017, 13: 178.","journal-title":"Alzheimers Dement"},{"key":"1525_CR27","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/alz.12398","volume":"18","author":"W Zhong","year":"2022","unstructured":"Zhong W, Wu A, Berglund K, Gu X, Jiang MQ, Talati J, et al. Pathogenesis of sporadic Alzheimer\u2019s disease by deficiency of NMDA receptor subunit GluN3A. Alzheimers Dement 2022, 18: 222\u2013239.","journal-title":"Alzheimers Dement"},{"key":"1525_CR28","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.neuropharm.2013.04.014","volume":"74","author":"RG Morris","year":"2013","unstructured":"Morris RG. NMDA receptors and memory encoding. Neuropharmacology 2013, 74: 32\u201340.","journal-title":"Neuropharmacology"},{"key":"1525_CR29","doi-asserted-by":"publisher","first-page":"S191","DOI":"10.33549\/physiolres.932678","volume":"63","author":"V Vyklicky","year":"2014","unstructured":"Vyklicky V, Korinek M, Smejkalova T, Balik A, Krausova B, Kaniakova M, et al. Structure, function, and pharmacology of NMDA receptor channels. Physiol Res 2014, 63: S191\u2013S203.","journal-title":"Physiol Res"},{"key":"1525_CR30","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/30748","volume":"393","author":"S Das","year":"1998","unstructured":"Das S, Sasaki YF, Rothe T, Premkumar LS, Takasu M, Crandall JE, et al. Increased NMDA current and spine density in mice lacking the NMDA receptor subunit NR3A. Nature 1998, 393: 377\u2013381.","journal-title":"Nature"},{"key":"1525_CR31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.pneurobio.2010.01.004","volume":"91","author":"MA Henson","year":"2010","unstructured":"Henson MA, Roberts AC, P\u00e9rez-Ota\u00f1o I, Philpot BD. Influence of the NR3A subunit on NMDA receptor functions. Prog Neurobiol 2010, 91: 23\u201337.","journal-title":"Prog Neurobiol"},{"key":"1525_CR32","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1002\/alz.13374","volume":"19","author":"SP Yu","year":"2023","unstructured":"Yu SP, Jiang M, Berglund K, Wei L. Strain hypothesis and additional evidence of the GluN3A deficiency-mediated pathogenesis of Alzheimer\u2019s disease. Alzheimers Dement 2023, 19: 4267\u20134269.","journal-title":"Alzheimers Dement"},{"key":"1525_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2014.08.014","volume":"36","author":"A Stargardt","year":"2015","unstructured":"Stargardt A, Swaab DF, Bossers K. Storm before the quiet: Neuronal hyperactivity and A\u03b2 in the presymptomatic stages of Alzheimer\u2019s disease. Neurobiol Aging 2015, 36: 1\u201311.","journal-title":"Neurobiol Aging"},{"key":"1525_CR34","doi-asserted-by":"publisher","first-page":"6697","DOI":"10.1096\/fj.201801751R","volume":"33","author":"X Wang","year":"2019","unstructured":"Wang X, Zheng W. Ca2+ homeostasis dysregulation in Alzheimer\u2019s disease: A focus on plasma membrane and cell organelles. FASEB J 2019, 33: 6697\u20136712.","journal-title":"FASEB J"},{"key":"1525_CR35","doi-asserted-by":"publisher","first-page":"9067","DOI":"10.3390\/ijms24109067","volume":"24","author":"D Baracaldo-Santamar\u00eda","year":"2023","unstructured":"Baracaldo-Santamar\u00eda D, Avenda\u00f1o-Lopez SS, Ariza-Salamanca DF, Rodriguez-Giraldo M, Calderon-Ospina CA, Gonz\u00e1lez-Reyes RE, et al. Role of calcium modulation in the pathophysiology and treatment of Alzheimer\u2019s disease. Int J Mol Sci 2023, 24: 9067.","journal-title":"Int J Mol Sci"},{"key":"1525_CR36","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/j.bbamcr.2018.07.018","volume":"1865","author":"BC Tong","year":"2018","unstructured":"Tong BC, Wu AJ, Li M, Cheung KH. Calcium signaling in Alzheimer\u2019s disease & therapies. Biochim Biophys Acta Mol Cell Res 2018, 1865: 1745\u20131760.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"1525_CR37","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2147\/NDT.S350939","volume":"18","author":"M Ge","year":"2022","unstructured":"Ge M, Zhang J, Chen S, Huang Y, Chen W, He L, et al. Role of calcium homeostasis in Alzheimer\u2019s disease. Neuropsychiatr Dis Treat 2022, 18: 487\u2013498.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1525_CR38","doi-asserted-by":"publisher","first-page":"344","DOI":"10.2174\/1567205017666200528162046","volume":"17","author":"E Popugaeva","year":"2020","unstructured":"Popugaeva E, Chernyuk D, Bezprozvanny I. Reversal of calcium dysregulation as potential approach for treating Alzheimer\u2019s disease. Curr Alzheimer Res 2020, 17: 344\u2013354.","journal-title":"Curr Alzheimer Res"},{"key":"1525_CR39","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1038\/s41380-022-01589-5","volume":"27","author":"S Li","year":"2022","unstructured":"Li S, Stern AM. Bioactive human Alzheimer brain soluble a\u03b2: Pathophysiology and therapeutic opportunities. Mol Psychiatry 2022, 27: 3182\u20133191.","journal-title":"Mol Psychiatry"},{"key":"1525_CR40","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2210766119","volume":"119","author":"M Habashi","year":"2022","unstructured":"Habashi M, Vutla S, Tripathi K, Senapati S, Chauhan PS, Haviv-Chesner A, et al. Early diagnosis and treatment of Alzheimer\u2019s disease by targeting toxic soluble A\u03b2 oligomers. Proc Natl Acad Sci U S A 2022, 119: e2210766119.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1525_CR41","doi-asserted-by":"publisher","first-page":"S567","DOI":"10.3233\/JAD-179941","volume":"64","author":"EN Cline","year":"2018","unstructured":"Cline EN, Bicca MA, Viola KL, Klein WL. The amyloid-\u03b2 oligomer hypothesis: Beginning of the third decade. J Alzheimers Dis 2018, 64: S567\u2013S610.","journal-title":"J Alzheimers Dis"},{"key":"1525_CR42","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1016\/j.neurobiolaging.2010.01.011","volume":"32","author":"R R\u00f6nicke","year":"2011","unstructured":"R\u00f6nicke R, Mikhaylova M, R\u00f6nicke S, Meinhardt J, Schr\u00f6der UH, F\u00e4ndrich M, et al. Early neuronal dysfunction by amyloid \u03b2 oligomers depends on activation of NR2B-containing NMDA receptors. Neurobiol Aging 2011, 32: 2219\u20132228.","journal-title":"Neurobiol Aging"},{"key":"1525_CR43","doi-asserted-by":"publisher","first-page":"6627","DOI":"10.1523\/JNEUROSCI.0203-11.2011","volume":"31","author":"S Li","year":"2011","unstructured":"Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ. Soluble A\u03b2 oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci 2011, 31: 6627\u20136638.","journal-title":"J Neurosci"},{"key":"1525_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.612856","volume":"13","author":"MQ Jiang","year":"2021","unstructured":"Jiang MQ, Yu SP, Wei ZZ, Zhong W, Cao W, Gu X, et al. Conversion of reactive astrocytes to induced neurons enhances neuronal repair and functional recovery after ischemic stroke. Front Aging Neurosci 2021, 13: 612856.","journal-title":"Front Aging Neurosci"},{"key":"1525_CR45","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement 2018, 14: 535\u2013562.","journal-title":"Alzheimers Dement"},{"key":"1525_CR46","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 2011, 7: 280\u2013292.","journal-title":"Alzheimers Dement"},{"key":"1525_CR47","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 2011, 7: 270\u2013279.","journal-title":"Alzheimers Dement"},{"key":"1525_CR48","doi-asserted-by":"publisher","first-page":"295","DOI":"10.5483\/BMBRep.2021.54.6.055","volume":"54","author":"G Son","year":"2021","unstructured":"Son G, Jahanshahi A, Yoo SJ, Boonstra JT, Hopkins DA, Steinbusch HWM, et al. Olfactory neuropathology in Alzheimer\u2019s disease: A sign of ongoing neurodegeneration. BMB Rep 2021, 54: 295\u2013304.","journal-title":"BMB Rep"},{"key":"1525_CR49","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41419-021-04237-y","volume":"12","author":"JV Andersen","year":"2021","unstructured":"Andersen JV, Skotte NH, Christensen SK, Polli FS, Shabani M, Markussen KH, et al. Hippocampal disruptions of synaptic and astrocyte metabolism are primary events of early amyloid pathology in the 5xFAD mouse model of Alzheimer\u2019s disease. Cell Death Dis 2021, 12: 954.","journal-title":"Cell Death Dis"},{"key":"1525_CR50","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1750-1326-8-2","volume":"8","author":"WA Eimer","year":"2013","unstructured":"Eimer WA, Vassar R. Neuron loss in the 5XFAD mouse model of Alzheimer\u2019s disease correlates with intraneuronal A\u03b242 accumulation and Caspase-3 activation. Mol Neurodegener 2013, 8: 2.","journal-title":"Mol Neurodegener"},{"key":"1525_CR51","doi-asserted-by":"publisher","first-page":"10129","DOI":"10.1523\/JNEUROSCI.1202-06.2006","volume":"26","author":"H Oakley","year":"2006","unstructured":"Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer\u2019s disease mutations: Potential factors in amyloid plaque formation. J Neurosci 2006, 26: 10129\u201310140.","journal-title":"J Neurosci"},{"key":"1525_CR52","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13041-024-01118-1","volume":"17","author":"A Azargoonjahromi","year":"2024","unstructured":"Azargoonjahromi A. The duality of amyloid-\u03b2: Its role in normal and Alzheimer\u2019s disease states. Mol Brain 2024, 17: 44.","journal-title":"Mol Brain"},{"key":"1525_CR53","doi-asserted-by":"publisher","first-page":"65","DOI":"10.5607\/en22004","volume":"31","author":"H Jeong","year":"2022","unstructured":"Jeong H, Shin H, Hong S, Kim Y. Physiological roles of monomeric amyloid-\u03b2 and implications for Alzheimer\u2019s disease therapeutics. Exp Neurobiol 2022, 31: 65\u201388.","journal-title":"Exp Neurobiol"},{"key":"1525_CR54","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1021\/acschemneuro.6b00278","volume":"8","author":"EP Lebois","year":"2017","unstructured":"Lebois EP, Schroeder JP, Esparza TJ, Bridges TM, Lindsley CW, Conn PJ, et al. Disease-modifying effects of M1 muscarinic acetylcholine receptor activation in an Alzheimer\u2019s disease mouse model. ACS Chem Neurosci 2017, 8: 1177\u20131187.","journal-title":"ACS Chem Neurosci"},{"key":"1525_CR55","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2174\/156720509788486536","volume":"6","author":"SA Funke","year":"2009","unstructured":"Funke SA, Birkmann E, Willbold D. Detection of Amyloid-beta aggregates in body fluids: A suitable method for early diagnosis of Alzheimer\u2019s disease? Curr Alzheimer Res 2009, 6: 285\u2013289.","journal-title":"Curr Alzheimer Res"},{"key":"1525_CR56","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12589","volume":"16","author":"L Bl\u00f6meke","year":"2024","unstructured":"Bl\u00f6meke L, Rehn F, Kraemer-Schulien V, Kutzsche J, Pils M, Bujnicki T, et al. A\u03b2 oligomers peak in early stages of Alzheimer\u2019s disease preceding tau pathology. Alz & Dem Diag Ass & Dis Mo 2024, 16: e12589.","journal-title":"Alz & Dem Diag Ass & Dis Mo"},{"key":"1525_CR57","doi-asserted-by":"publisher","first-page":"16086","DOI":"10.1038\/s41598-024-66970-6","volume":"14","author":"JR Haynes","year":"2024","unstructured":"Haynes JR, Whitmore CA, Behof WJ, Landman CA, Ong HH, Feld AP, et al. Targeting soluble amyloid-beta oligomers with a novel nanobody. Sci Rep 2024, 14: 16086.","journal-title":"Sci Rep"},{"key":"1525_CR58","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1113\/JP279345","volume":"598","author":"A Marcantoni","year":"2020","unstructured":"Marcantoni A, Cerullo MS, Buxeda P, Tomagra G, Giustetto M, Chiantia G, et al. Amyloid Beta42 oligomers up-regulate the excitatory synapses by potentiating presynaptic release while impairing postsynaptic NMDA receptors. J Physiol 2020, 598: 2183\u20132197.","journal-title":"J Physiol"},{"key":"1525_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.834962","volume":"10","author":"DX Huang","year":"2022","unstructured":"Huang DX, Yu X, Yu WJ, Zhang XM, Liu C, Liu HP, et al. Calcium signaling regulated by cellular membrane systems and calcium homeostasis perturbed in Alzheimer\u2019s disease. Front Cell Dev Biol 2022, 10: 834962.","journal-title":"Front Cell Dev Biol"},{"key":"1525_CR60","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ceca.2018.09.003","volume":"76","author":"P Toglia","year":"2018","unstructured":"Toglia P, Demuro A, Mak DD, Ullah G. Data-driven modeling of mitochondrial dysfunction in Alzheimer\u2019s disease. Cell Calcium 2018, 76: 23\u201335.","journal-title":"Cell Calcium"},{"key":"1525_CR61","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1750-1326-9-48","volume":"9","author":"S Tu","year":"2014","unstructured":"Tu S, Okamoto S, Lipton SA, Xu H. Oligomeric A\u03b2-induced synaptic dysfunction in Alzheimer\u2019s disease. Mol Neurodegener 2014, 9: 48.","journal-title":"Mol Neurodegener"},{"key":"1525_CR62","doi-asserted-by":"publisher","first-page":"552","DOI":"10.2174\/156720511796391917","volume":"8","author":"J Brito-Moreira","year":"2011","unstructured":"Brito-Moreira J, Paula-Lima AC, Bomfim TR, Oliveira FB, Sep\u00falveda FJ, De Mello FG, et al. A\u03b2 oligomers induce glutamate release from hippocampal neurons. Curr Alzheimer Res 2011, 8: 552\u2013562.","journal-title":"Curr Alzheimer Res"},{"key":"1525_CR63","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1021\/acsbiomaterials.0c01583","volume":"7","author":"J Yin","year":"2021","unstructured":"Yin J, VanDongen AM. Enhanced neuronal activity and asynchronous calcium transients revealed in a 3D organoid model of Alzheimer\u2019s disease. ACS Biomater Sci Eng 2021, 7: 254\u2013264.","journal-title":"ACS Biomater Sci Eng"},{"key":"1525_CR64","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1001\/jamapsychiatry.2015.1309","volume":"72","author":"A Heck","year":"2015","unstructured":"Heck A, Fastenrath M, Coynel D, Auschra B, Bickel H, Freytag V, et al. Genetic analysis of association between calcium signaling and hippocampal activation, memory performance in the young and old, and risk for sporadic Alzheimer disease. JAMA Psychiatry 2015, 72: 1029\u20131036.","journal-title":"JAMA Psychiatry"},{"key":"1525_CR65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0074203","volume":"8","author":"F Rubio-Moscardo","year":"2013","unstructured":"Rubio-Moscardo F, Set\u00f3-Salvia N, Pera M, Bosch-Morat\u00f3 M, Plata C, Belbin O, et al. Rare variants in calcium homeostasis modulator 1 (CALHM1) found in early onset Alzheimer\u2019s disease patients alter calcium homeostasis. PLoS One 2013, 8: e74203.","journal-title":"PLoS One"},{"key":"1525_CR66","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/j.1476-5381.2012.02057.x","volume":"167","author":"W Danysz","year":"2012","unstructured":"Danysz W, Parsons CG. Alzheimer\u2019s disease, \u03b2-amyloid, glutamate, NMDA receptors and memantine\u2014searching for the connections. Br J Pharmacol 2012, 167: 324\u2013352.","journal-title":"Br J Pharmacol"},{"key":"1525_CR67","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s11571-022-09815-0","volume":"17","author":"A Pawar","year":"2023","unstructured":"Pawar A, Pardasani KR. Effect of disturbances in neuronal calcium and IP3 dynamics on \u03b2-amyloid production and degradation. Cogn Neurodyn 2023, 17: 239\u2013256.","journal-title":"Cogn Neurodyn"},{"key":"1525_CR68","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1126\/science.aay0198","volume":"365","author":"B Zott","year":"2019","unstructured":"Zott B, Simon MM, Hong W, Unger F, Chen-Engerer HJ, Frosch MP, et al. A vicious cycle of \u03b2 amyloid-dependent neuronal hyperactivation. Science 2019, 365: 559\u2013565.","journal-title":"Science"},{"key":"1525_CR69","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13195-021-00859-8","volume":"13","author":"Y Li","year":"2021","unstructured":"Li Y, Zhu K, Li N, Wang X, Xiao X, Li L, et al. Reversible GABAergic dysfunction involved in hippocampal hyperactivity predicts early-stage Alzheimer disease in a mouse model. Alzheimers Res Ther 2021, 13: 114.","journal-title":"Alzheimers Res Ther"},{"key":"1525_CR70","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1093\/brain\/awae126","volume":"147","author":"AJ Barbour","year":"2024","unstructured":"Barbour AJ, Gourmaud S, Lancaster E, Li X, Stewart DA, Hoag KF, et al. Seizures exacerbate excitatory: Inhibitory imbalance in Alzheimer\u2019s disease and 5XFAD mice. Brain 2024, 147: 2169\u20132184.","journal-title":"Brain"},{"key":"1525_CR71","doi-asserted-by":"publisher","first-page":"17680","DOI":"10.1523\/JNEUROSCI.4740-11.2011","volume":"31","author":"D Putcha","year":"2011","unstructured":"Putcha D, Brickhouse M, O\u2019Keefe K, Sullivan C, Rentz D, Marshall G, et al. Hippocampal hyperactivation associated with cortical thinning in Alzheimer\u2019s disease signature regions in non-demented elderly adults. J Neurosci 2011, 31: 17680\u201317688.","journal-title":"J Neurosci"},{"key":"1525_CR72","doi-asserted-by":"publisher","first-page":"S487","DOI":"10.3233\/JAD-2010-100306","volume":"20","author":"C Supnet","year":"2010","unstructured":"Supnet C, Bezprozvanny I. Neuronal calcium signaling, mitochondrial dysfunction, and Alzheimer\u2019s disease. J Alzheimers Dis 2010, 20: S487\u2013S498.","journal-title":"J Alzheimers Dis"},{"key":"1525_CR73","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/jnr.22172","volume":"88","author":"GM Alley","year":"2010","unstructured":"Alley GM, Bailey JA, Chen D, Ray B, Puli LK, Tanila H, et al. Memantine lowers amyloid-beta peptide levels in neuronal cultures and in APP\/PS1 transgenic mice. J Neurosci Res 2010, 88: 143\u2013154.","journal-title":"J Neurosci Res"},{"key":"1525_CR74","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ejphar.2017.02.001","volume":"798","author":"K Ito","year":"2017","unstructured":"Ito K, Tatebe T, Suzuki K, Hirayama T, Hayakawa M, Kubo H, et al. Memantine reduces the production of amyloid-\u03b2 peptides through modulation of amyloid precursor protein trafficking. Eur J Pharmacol 2017, 798: 16\u201325.","journal-title":"Eur J Pharmacol"},{"key":"1525_CR75","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/s00018-022-04438-4","volume":"79","author":"J Companys-Alemany","year":"2022","unstructured":"Companys-Alemany J, Turcu AL, Schneider M, M\u00fcller CE, V\u00e1zquez S, Gri\u00f1\u00e1n-Ferr\u00e9 C, et al. NMDA receptor antagonists reduce amyloid-\u03b2 deposition by modulating calpain-1 signaling and autophagy, rescuing cognitive impairment in 5XFAD mice. Cell Mol Life Sci 2022, 79: 408.","journal-title":"Cell Mol Life Sci"},{"key":"1525_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109737","volume":"244","author":"P Karimi Tari","year":"2024","unstructured":"Karimi Tari P, Parsons CG, Collingridge GL, Rammes G. Memantine: Updating a rare success story in pro-cognitive therapeutics. Neuropharmacology 2024, 244: 109737.","journal-title":"Neuropharmacology"},{"key":"1525_CR77","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.mehy.2012.04.042","volume":"79","author":"RB Lu","year":"2012","unstructured":"Lu RB, Chen SL, Lee SY, Chang YH, Chen SH, Chu CH, et al. Neuroprotective and neurogenesis agent for treating bipolar II disorder: Add-on memantine to mood stabilizer works. Med Hypotheses 2012, 79: 280\u2013283.","journal-title":"Med Hypotheses"},{"key":"1525_CR78","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.expneurol.2016.08.007","volume":"287","author":"H Izumida","year":"2017","unstructured":"Izumida H, Takagi H, Fujisawa H, Iwata N, Nakashima K, Takeuchi S, et al. NMDA receptor antagonist prevents cell death in the hippocampal dentate gyrus induced by hyponatremia accompanying adrenal insufficiency in rats. Exp Neurol 2017, 287: 65\u201374.","journal-title":"Exp Neurol"},{"key":"1525_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108102","volume":"171","author":"LF Jaimes","year":"2020","unstructured":"Jaimes LF, Mansk LMZ, Almeida-Santos AF, Pereira GS. Maturation of newborn neurons predicts social memory persistence in mice. Neuropharmacology 2020, 171: 108102.","journal-title":"Neuropharmacology"},{"key":"1525_CR80","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.euroneuro.2005.06.005","volume":"16","author":"D Van Dam","year":"2006","unstructured":"Van Dam D, De Deyn PP. Cognitive evaluation of disease-modifying efficacy of galantamine and memantine in the APP23 model. Eur Neuropsychopharmacol 2006, 16: 59\u201369.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1525_CR81","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.pbb.2016.03.002","volume":"144","author":"L Devi","year":"2016","unstructured":"Devi L, Ohno M. Cognitive benefits of memantine in Alzheimer\u2019s 5XFAD model mice decline during advanced disease stages. Pharmacol Biochem Behav 2016, 144: 60\u201366.","journal-title":"Pharmacol Biochem Behav"},{"key":"1525_CR82","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000486546","volume":"45","author":"R Knight","year":"2018","unstructured":"Knight R, Khondoker M, Magill N, Stewart R, Landau S. A systematic review and meta-analysis of the effectiveness of acetylcholinesterase inhibitors and memantine in treating the cognitive symptoms of dementia. Dement Geriatr Cogn Disord 2018, 45: 131\u2013151.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1525_CR83","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1200\/JCO.19.02767","volume":"38","author":"PD Brown","year":"2020","unstructured":"Brown PD, Gondi V, Pugh S, Tome WA, Wefel JS, Armstrong TS, et al. Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: Phase III trial NRG oncology CC001. J Clin Oncol 2020, 38: 1019\u20131029.","journal-title":"J Clin Oncol"},{"key":"1525_CR84","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1056\/NEJMoa013128","volume":"348","author":"B Reisberg","year":"2003","unstructured":"Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ, Memantine Study, G. Memantine in moderate-to-severe Alzheimer\u2019s disease. N Engl J Med. 2003, 348: 1333\u20131341. https:\/\/doi.org\/10.1056\/NEJMoa013128.","journal-title":"N Engl J Med."},{"key":"1525_CR85","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/WAD.0b013e318065c495","volume":"21","author":"CH van Dyck","year":"2007","unstructured":"van Dyck CH, Tariot PN, Meyers B, Malca Resnick E. Memantine MEM-MD-01 Study Group. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord 2007, 21: 136\u2013143.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"1525_CR86","unstructured":"Kuns B, Rosani A, Patel P, Varghese D. Memantine. 2024 Jan 31. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan. PMID: 29763201."},{"key":"1525_CR87","first-page":"773","volume":"41","author":"K Ditzler","year":"1991","unstructured":"Ditzler K. Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial. Arzneimittelforschung 1991, 41: 773\u2013780.","journal-title":"Arzneimittelforschung"},{"key":"1525_CR88","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123289","volume":"10","author":"S Matsunaga","year":"2015","unstructured":"Matsunaga S, Kishi T, Iwata N. Memantine monotherapy for Alzheimer\u2019s disease: A systematic review and meta-analysis. PLoS One 2015, 10: e0123289.","journal-title":"PLoS One"},{"key":"1525_CR89","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/0922-4106(91)90113-V","volume":"206","author":"J Kornhuber","year":"1991","unstructured":"Kornhuber J, Bormann J, H\u00fcbers M, Rusche K, Riederer P. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: A human postmortem brain study. Eur J Pharmacol 1991, 206: 297\u2013300.","journal-title":"Eur J Pharmacol"},{"key":"1525_CR90","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0028-3908(98)00161-0","volume":"38","author":"CG Parsons","year":"1999","unstructured":"Parsons CG, Danysz W, Bartmann A, Spielmanns P, Frankiewicz T, Hesselink M, et al. Amino-alkyl-cyclohexanes are novel uncompetitive NMDA receptor antagonists with strong voltage-dependency and fast blocking kinetics: in vitro and in vivo characterization. Neuropharmacology 1999, 38: 85\u2013108.","journal-title":"Neuropharmacology"},{"key":"1525_CR91","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1097\/FBP.0b013e3283123cad","volume":"19","author":"L Mor\u00e8","year":"2008","unstructured":"Mor\u00e8 L, Gravius A, Nagel J, Valastro B, Greco S, Danysz W. Therapeutically relevant plasma concentrations of memantine produce significant L-N-methyl-D-aspartate receptor occupation and do not impair learning in rats. Behav Pharmacol 2008, 19: 724\u2013734.","journal-title":"Behav Pharmacol"},{"key":"1525_CR92","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00210-007-0235-x","volume":"376","author":"GZ R\u00e9us","year":"2008","unstructured":"R\u00e9us GZ, Valvassori SS, Machado RA, Martins MR, Gavioli EC, Quevedo J. Acute treatment with low doses of memantine does not impair aversive, non-associative and recognition memory in rats. Naunyn Schmiedebergs Arch Pharmacol 2008, 376: 295\u2013300.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"1525_CR93","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.clpt.2005.10.005","volume":"79","author":"A Periclou","year":"2006","unstructured":"Periclou A, Ventura D, Rao N, Abramowitz W. Pharmacokinetic study of memantine in healthy and renally impaired subjects. Clin Pharmacol Ther 2006, 79: 134\u2013143.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Neuroscience Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12264-025-01525-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12264-025-01525-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12264-025-01525-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T08:03:36Z","timestamp":1785485016000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12264-025-01525-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,25]]},"references-count":93,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1525"],"URL":"https:\/\/doi.org\/10.1007\/s12264-025-01525-x","relation":{},"ISSN":["1673-7067","1995-8218"],"issn-type":[{"value":"1673-7067","type":"print"},{"value":"1995-8218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,25]]},"assertion":[{"value":"27 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that there are no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Ethics"}}]}}